Sosei Heptares Webinar Presentation for FY2022 Financial Results
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, will announce its earnings results and present operational highlights for the 12 months ended 31 December 2022 on Tuesday, 14 February 2023.
The Company will host a webinar presentation in-person and virtually for institutional investors, securities analysts and the press with Chris Cargill, President and CEO, and Hironoshin Nomura, CFO at 5 pm JST (8 am GMT) in Tokyo.
The webinar is open to all existing and potential investors as well and will consist of a presentation followed by a Q&A session. Please click here to pre-register, which will provide a link to access the webinar. Japanese/English simultaneous interpretation will be provided.
Presentation slides will be made available by 3:30 pm JST (6:30 am GMT) on 14 February 2023 through the investor section of the Company’s Home Page here. Archive streaming will be available here on the company’s website after the event.
About Sosei Heptares
We have established partnerships with some of the world’s leading pharmaceutical companies and multiple emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.
Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, Chief Financial Officer
MEDiSTRAVA Consulting (for International Media)